ALKERMES, INC. for ALKERMES, INC.
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Patient access and maintain six protected classes for depressions and schizophrenia under Medicare Part D; Inflation Reduction Act of 2022 implementation, Part D redesign phase in for small companies; Medicaid Drug Rebate Program proposed rule Misclassification of Drugs, Program Administration and Program Integrity Updates Under the Medicaid Drug Rebate Program;
| Lobbyist | Covered position, as disclosed |
|---|---|
| ZACHARY MICHAEL MARSHALL | — |
| PETER NORMAN | — |
Health Issues HCR
Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 2163/S. 464 the Safe Step Act; Policies impacting pharmaceutical development, reimbursement, and patient access and cost; H.R. 5539 - ORPHAN Cures Act; P.L. 115-97 - Tax Cuts and Jobs Act of 2017, Orphan Drug Tax Credit; Awareness of need for transparency and patient access within the 340B program; H.R. 9029 Labor, Health and Human Services, Education Appropriations, 2025; H.R. 9026 Commerce, Justice, Science, and Related Agencies Appropriations, 2025; H.R. 8580 Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2025; H.R. 9747 Continuing Appropriations and Extensions Act, 2025 PDUFA implementation and efficiency improvements at the FDA;
| Lobbyist | Covered position, as disclosed |
|---|---|
| WILLIAM PATRICK HIBBS | — |
| ZACHARY MICHAEL MARSHALL | — |
| PETER NORMAN | — |
Alcohol and Drug Abuse ALC
Expand funding and flexibility to address all substance use disorders;
| Lobbyist | Covered position, as disclosed |
|---|---|
| WILLIAM PATRICK HIBBS | — |
| ZACHARY MICHAEL MARSHALL | — |
| PETER NORMAN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.